Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARD | Q03181 | 1/20 | 0.34 |
| ▸ | LY96 | Q9Y6Y9 | 6/20 | 0.33 |
| ▸ | TLR4 | O00206 | 5/20 | 0.33 |
| ▸ | PPIP5K2 | O43314 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3075859 | 0.86 | ALDH1A1 (0.38) | PPARDLY96TLR4 | |
| SCHEMBL3080244 | 0.83 | LY96 (0.43) | LY96TLR4 | |
| SCHEMBL3086364 | 0.82 | ITPR3 (0.46) | LY96TLR4PPIP5K2 | |
| SCHEMBL3073446 | 0.82 | ITPR3 (0.46) | LY96TLR4PPIP5K2 | |
| SCHEMBL3085410 | 0.82 | MEN1 (0.34) | — | |
| SCHEMBL3080744 | 0.82 | LY96 (0.47) | LY96TLR4 | |
| SCHEMBL8446159 | 0.78 | ITPR3 (0.35) | LY96TLR4 | |
| SCHEMBL1149696 | 0.77 | ALDH1A1 (0.41) | — | |
| SCHEMBL12858644 | 0.77 | ALDH1A1 (0.41) | — | |
| SCHEMBL3075449 | 0.76 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100261682-A1 | Method and Means for the Treatment of Cachexia | BIONERIS AB | 2010-10-14 | — | — | US | claimed |
| US-20160074421-A1 | METHOD FOR THE TREATMENT OF DISEASES CAUSED BY HAEMORRHAGIC VIRUSES AND COMPOUNDS FOR USE IN SAID TREATMENT | SIRÈN MATTI (FI) | 2016-03-17 | — | — | US | disclosed |
| US-20100261682-A1 | Method and Means for the Treatment of Cachexia | BIONERIS AB | 2010-10-14 | — | — | US | disclosed |
| US-20090175924-A1 | COATED STENT | BIONERIS AB (SE) | 2009-07-09 | — | — | US | disclosed |
| EP-1390045-B1 | THE USE OF A COMPOUND WITH A NEGATIVELY CHARGED DOMAIN OF PHOSPHOROUS-CONTAINING RADICALS FOR THE TREATMENT OF RESTENOSIS | BIONERIS AB (SE) | 2008-12-03 | — | — | EP | disclosed |
| US-20050227946-A1 | METHOD OF TREATING INFLAMMATORY, TISSUE REPAIR AND INFECTIOUS CONDITIONS | PERSTORP AB (SE) | 2005-10-13 | — | — | US | disclosed |
| US-6949517-B1 | Method of treating inflammatory, tissue repair and infectious conditions | SIREN MATTI | 2005-09-27 | — | — | US | disclosed |
| US-20040235799-A1 | Use of a compound with a negatively charged domain of radicals for the treatment of restenosis | BIONERIS AB (SE) | 2004-11-25 | — | — | US | disclosed |
| US-6632797-B2 | Administering to a mammal a cyclic compound (acyclic, carbocyclic or heterocyclic) substituted by at least three vicinal phosphorus containing radicals for treating angiogenesis in tumor conditions | SIREN MATTI (FI) | 2003-10-14 | — | — | US | disclosed |
| EP-1216705-A2 | The use of growth factor modulation compounds substituted with three vicinal phosphorus containing radical in the manufacture of a medicament for tissue repair | PERSTORP AB (SE) | 2002-06-26 | — | — | EP | disclosed |
| US-20020065253-A1 | Use of growth factor modulating compounds | SIREN MATTI (FI) | 2002-05-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100261682-A1 | Method and Means for the Treatment of Cachexia | PYGM, GYS1, CPT1B | PPARD 455/4885LY96 3278/4885TLR4 2430/4885 |
| US-20020065253-A1 | Use of growth factor modulating compounds | HDGF, PGF, FGF2 | PPARD 2832/4885LY96 1810/4885TLR4 287/4885 |
| US-20160074421-A1 | METHOD FOR THE TREATMENT OF DISEASES CAUSED BY HAEMORRHAGIC VIRUSES AND COMPOUNDS FOR USE IN SAID TREATMENT | TTPA, LPO, HADHB | PPARD 284/4885LY96 865/4885TLR4 741/4885 |
| US-20040235799-A1 | Use of a compound with a negatively charged domain of radicals for the treatment of restenosis | PCNA, OPRK1, OGFR | PPARD 1994/4885LY96 3381/4885TLR4 358/4885 |
| US-20090175924-A1 | COATED STENT | PHOSPHO1, SOST, PLCB3 | PPARD 3795/4885LY96 2565/4885TLR4 199/4885 |
| US-20050227946-A1 | METHOD OF TREATING INFLAMMATORY, TISSUE REPAIR AND INFECTIOUS CONDITIONS | TNF, TLR2, TPMT | PPARD 2645/4885LY96 1159/4885TLR4 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.